8-K/A: Shuttle Pharmaceuticals Corrects Warrant Disclosure

Shuttle Pharmaceuticals Holdings, Inc. amends prior filing to clarify the actual number of pre-funded warrants issued as of September 9, 2026.

Summary

• This filing is an amendment (Form 8-K/A) to a previous Current Report on Form 8-K filed on September 15, 2026.
• The amendment corrects Item 3.02 concerning the issuance of pre-funded warrants.
• The original filing stated that approximately 16,932,508 shares of Common Stock could be purchased via pre-funded warrants, representing the maximum possible issuance.
• This amended filing clarifies that as of September 9, 2026, the actual number of pre-funded warrants issued was 9,741,751.
• No other modifications or updates are made to the original Form 8-K.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to a correction of previously disclosed information regarding warrant issuance, indicating a potential for miscommunication or initial inaccuracy in reporting.

Negatives

• The company had to amend a previous filing to correct the number of pre-funded warrants issued.
• The initial disclosure may have caused confusion regarding the actual number of warrants issued and outstanding.

Risks

• Potential for investor confusion or distrust due to the correction of previously disclosed information.
• The actual number of issued warrants (9,741,751) is significantly lower than the previously stated maximum potential issuance (16,932,508), which could impact dilution expectations.

Future Outlook

No specific forward-looking statements or guidance were provided in this amendment, as it solely corrects a previous disclosure.

Management Comments

• The Company hereby amends the Form 8-K to reflect that, as of September 9, 2026, the actual number of Pre-Funded Warrants that have been issued is 9,741,751.
• There are no other modifications or updates to any of the information made in the Form 8-K.

Industry Context

StockSavvy.ai notes that accurate and timely disclosure of share and warrant issuances is critical in the pharmaceutical and biotech sectors, where capital raises are frequent and investor perception of dilution is a key valuation driver. Corrections like this, while necessary, can temporarily impact market confidence.

Stakeholder Impact

• Shareholders may be concerned about the accuracy of previous disclosures and the potential for dilution from the actual number of warrants issued.
• Investors relying on the initial disclosure may need to reassess their understanding of the company's outstanding equity.

Key Dates

Keywords

warrants, pre-funded warrants, amendment, disclosure, share issuance, capital markets